FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on an analysis of potential risk factors, adult patients who received MYLOTARG as monotherapy, either before or after an haematopoietic stem cell transplant (HSCT), and patients with moderate or severe hepatic impairment are at increased risk for developing VOD (see section 4.8).
Slovenian: Na podlagi analize potencialnih dejavnikov tveganja je tveganje za razvoj VOD večje pri odraslih bolnikih, ki zdravilo MYLOTARG prejemajo kot monoterapijo, bodisi pred presaditvijo krvotvornih matičnih celic (PKMC) ali po njej, ter pri bolnikih z zmerno ali hudo okvaro jeter (glejte poglavje 4.8).
English: Event-free survival (by Investigator)
Slovenian: Preživetje brez dogodkov (po oceni raziskovalca)
English: Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0)1 52 11 400
Slovenian: Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0)1 52 11 400
English: Management of some adverse reactions may require dose interruptions or permanent discontinuation of MYLOTARG (see sections 4.4 and 4.8).
Slovenian: Za obvladovanje nekaterih neželenih učinkov bo morda potrebna prekinitev odmerjanja ali trajna prekinitev zdravljenja z zdravilom MYLOTARG (glejte poglavji 4.4 in 4.8).
English: If not used immediately, store at room temperature (below 25°C) for up to 6 hours.
Slovenian: Če raztopine ne uporabite takoj, jo hranite na sobni temperaturi (do 25 °C) za največ 6 ur.
English: If a second induction is required, MYLOTARG should not be administered during second induction therapy.
Slovenian: Če je potrebna druga indukcija, zdravila MYLOTARG ne smete uporabljati med drugim indukcijskim zdravljenjem.
English: Treatment-related death due to septic shock was reported in 1 (0.8%) patients.
Slovenian: Pri 1 bolniku (0,8 %) so poročali o smrti, povezani z zdravljenjem, in sicer zaradi septičnega šoka.
English: Effects on liver, kidney and male reproductive organs in rats, and on lymphoid tissues in monkeys (approximately 18 times for rats, and 36 times for monkeys, the human clinical exposure after the third human dose of 3 mg/m2 based on AUC168) were not reversible.
Slovenian: Učinki na jetra, ledvice in moške reprodukcijske organe pri podganah ter na limfatična tkiva pri opicah (pri podganah približno 18kratnik klinične izpostavljenosti pri ljudeh in pri opicah 36-kratnik klinične izpostavljenosti pri ljudeh po tretjem odmerku 3 mg/m2 na podlagi vrednosti AUC168) niso bili reverzibilni.
English: • Complication known as tumour lysis syndrome Tell your doctor right away if you experience dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances.
Slovenian: • Zaplet, znan kot sindrom tumorske lize Nemudoma obvestite zdravnika, če se vam pojavijo omotica, zmanjšano uriniranje, zmedenost, bruhanje, občutek siljenja na bruhanje, otekanje, kratka sapa ali motnje srčnega ritma.
English: ***MYLOTARG in the treatment of relapsed AML (9 mg/m2).
Slovenian: Zdravilo MYLOTARG za zdravljenje recidivne AML (9 mg/m Posamezni primeri.
English: Almost all patients (>90 %) experienced myelosuppression across studies a: When MYLOTARG was given in combination, cytarabine was part of the combination studied in 8 out of the 9 studies.
Slovenian: Mielosupresija a: Kadar so zdravilo MYLOTARG dajali v kombinaciji, je bil citarabin del preučevane kombinacije v 8 od 9 študij.
English: • If neutrophil count does not recover to greater than 500/mm3 within 14 days following the planned start date of the consolidation cycle (14 days after haematologic recovery following previous cycle), discontinue MYLOTARG (do not administer MYLOTARG in the consolidation cycles).
Slovenian: 14 dneh po načrtovanem datumu začetka konsolidacijskega cikla (14 dni po hematološkem okrevanju, ki je sledilo prejšnjemu ciklu), prekinite zdravljenje z zdravilom MYLOTARG (ne dajajte zdravila MYLOTARG v konsolidacijskih ciklih).
English: MYLOTARG should not be administered during second induction.
Slovenian: Zdravila MYLOTARG ne smete uporabljati med drugo indukcijo.
English: See section 2, “MYLOTARG contains sodium”.
Slovenian: Glejte poglavje 2, “Zdravilo MYLOTARG
English: Women of childbearing potential, or partners of females of childbearing potential should be advised to use 2 methods of effective contraception during treatment with MYLOTARG for at least 7 months (females) or 4 months (males) after the last dose (see section 4.6).
Slovenian: Ženskam v rodni dobi ali partnerjem žensk v rodni dobi je treba svetovati, naj med zdravljenjem z zdravilom MYLOTARG uporabljajo 2 metodi učinkovite kontracepcije še vsaj 7 mesecev (ženske) ali 4 mesece (moški) po zadnjem odmerku (glejte poglavje 4.6).
English: Schedule modification for hyperleukocytosis
Slovenian: Prilagajanje sheme odmerjanja pri hiperlevkocitozi
English: Overall survival by AML risk classifications from study ALFA-0701 (mITT Population) MYLOTARG + daunorubicin + cytarabine daunorubicin + cytarabine
Slovenian: Preživetje brez dogodkov po oceni raziskovalca in po klasifikacijah tveganja za AML iz študije ALFA-0701 (populacija mITT) zdravilo MYLOTARG + daunorubicin + citarabin daunorubicin + citarabin
English: The pharmacokinetics (PK) of gemtuzumab ozogamicin is described by measuring PK characteristics of the antibody (hP67.6) as well as total and unconjugated calicheamicin derivatives.
Slovenian: Farmakokinetiko gemtuzumab ozogamicina so opisali z merjenjem farmakokinetičnih značilnosti protitelesa (hP67.6) ter celokupnih in nekonjugiranih derivatov kaliheamicina.
English: No dose adjustment is required in patients with mild to moderate renal impairment.
Slovenian: Pri bolnikih z blago do zmerno okvaro ledvic prilagajanje odmerka ni potrebno.
English: Persistent neutropenia
Slovenian: perzistentna nevtropenija
English: In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide is a substrate of P-glycoprotein (P-gp).
Slovenian: N-acetil-gama-kaliheamicin dimetilhidrazid je in vitro substrat glikoproteina P (P-gp).
English: Τηλ: +357 22 817690
Slovenian: (Cyprus Branch) Τηλ: +357 22 817690
English: If not used immediately, store at room temperature (below 25°C) for up to 6 hours, which includes the 2-hour infusion time and 1 hour, if needed, to allow the refrigerated diluted solution to equilibrate to room temperature (below 25°C).
Slovenian: Če raztopine ne boste uporabili takoj, jo shranite na sobni temperaturi (do 25 °C) za največ 6 ur, kar vključuje 2 uri infundiranja in, če je treba, 1 uro, da se ohlajena razredčena raztopina segreje na sobno temperaturo (do 25 °C).
English: Dose and schedule modifications
Slovenian: Prilagajanje odmerkov in sheme odmerjanja
English: However, the optimal dose of gemtuzumab ozogamicin for paediatric patients was not established, since in Study AAML0531 during the second intensification period after the second dose of gemtuzumab ozogamicin, a larger proportion of patients in the gemtuzumab ozogamicin arm experienced prolonged neutrophil recovery time (> 59 days) as compared with the comparator arm (21.0% versus 11.5%), and more patients died during remission (5.5% versus 2.8%).
Slovenian: Kljub temu pri pediatričnih bolnikih še niso ugotovili optimalnega odmerka gemtuzumab ozogamicina, saj se je v študiji AAML0531 v drugem obdobju intenzifikacije po drugem odmerku gemtuzumab ozogamicina pri večjem deležu bolnikov v skupini, ki je prejemala gemtuzumab ozogamicin, čas do povečanja števila nevtrofilcev podaljšal (> 59 dni) v primerjavi s primerjalno skupino (21,0 % v primerjavi z 11,5 %), med remisijo pa je umrlo več bolnikov (5,5 % v primerjavi z
English: • The other ingredients are dextran 40, sucrose, sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous.
Slovenian: • Druge sestavine zdravila so dekstran 40, saharoza, natrijev klorid, natrijev dihidrogenfosfat monohidrat, brezvodni dinatrijev hidrogenfosfat.
English: • Your doctor or nurse will decide on the correct dose.
Slovenian: • Pravi odmerek bosta določila zdravnik ali medicinska sestra.
English: Based on population pharmacokinetic (PK) analyses, the combination of gemtuzumab ozogamicin with DNR and AraC is not predicted to cause clinically meaningful changes in the PK of these agents.
Slovenian: Na podlagi populacijskih farmakokinetičnih analiz kombinacija gemtuzumab ozogamicina z daunorubicinom in citarabinom predvidoma ne povzroči klinično pomembnih sprememb v farmakokinetiki teh zdravil.
English: Use in patients with hepatic impairment
Slovenian: Uporaba pri bolnikih z okvaro ledvic
English: In the completed randomised paediatric Phase 3 Study AAML0531 (see section 5.1) of gemtuzumab ozogamicin combined with intensive first-line therapy in 1,063 newly diagnosed children (93.7% of patients <18 years of age), and young adults (6.3% of patients) with de novo AML aged 0 to 29 years, the safety profile was similar with that observed in the other studies of gemtuzumab ozogamicin combined with intensive chemotherapy in adult patients with de novo AML.
Slovenian: V zaključeni randomizirani pediatrični študiji 3. faze AAML0531 (glejte poglavje 5.1), v kateri so preučevali gemtuzumab ozogamicin v kombinaciji z intenzivnim zdravljenjem v prvi liniji pri 1.063 na novo diagnosticiranih otrocih (93,7 % bolnikov < 18 let) in mladostnikih (6,3 % bolnikov) z AML de novo, starih od 0 do 29 let, je bil varnostni profil podoben varnostnemu profilu v drugih študijah gemtuzumab ozogamicina v kombinaciji z intenzivno kemoterapijo pri odraslih bolnikih z AML de novo.
English: The efficacy of MYLOTARG has been shown in AML patients with favourable- and intermediate-risk cytogenetics, with uncertainty regarding the size of the effect in patients with adverse cytogenetics (see section 5.1).
Slovenian: Učinkovitost zdravila MYLOTARG so dokazali pri bolnikih z AML s citogenetsko ugodnim in zmernim tveganjem, velikost učinka pri bolnikih z neugodnim citogenetskim tveganjem pa je bila negotova (glejte poglavje 5.1).
English: • infusion reaction: experience during or shortly after MYLOTARG infusion symptoms such as dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath, or heart rhythm disturbances (this may be a potentially life-threatening complication known as tumour lysis syndrome).
Slovenian: • reakcija na infuzijo: se vam med infundiranjem zdravila MYLOTARG ali kmalu po njem pojavijo simptomi, kot so omotica, zmanjšano uriniranje, zmedenost, bruhanje, občutek siljenja na bruhanje, otekanje, kratka sapa ali motnje srčnega ritma (to je lahko življenjsko ogrožajoč zaplet, imenovan sindrom tumorske lize).
English: d. 2-sided p-value from the log-rank test. e. Response defined as CR+CRp.
Slovenian: Odziv, opredeljen kot CR + CRp.
English: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanised immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin.
Slovenian: Gemtuzumab ozogamicin je imunokonjugat (ADC - Antibody-Drug Conjugate), sestavljen iz monoklonskega protitelesa, ki je usmerjeno proti CD33 (hP67.6; rekombinantni humanizirani imunoglobulin [Ig] G4, protitelo kapa, pridobljeno iz celične kulture sesalcev v celicah NS0) in kovalentno vezano na citotoksično učinkovino N-acetil-gama-kaliheamicin.
English: The study showed that addition of MYLOTARG to intensive chemotherapy improved EFS (3 years: 50.6% versus 44.0%; HR 0.838; 95% CI: 0.706, 0.995; p=0.0431) in de novo AML owing to a reduced relapse risk, with a trend towards longer OS in the MYLOTARG arm which was not statistically significant (3 years: 72.4% versus 67.6%; HR 0.904; 95% CI: 0.721, 1.133; p=0.3799).
Slovenian: Rezultati študije so pokazali izboljšanje EFS pri intenzivni kemoterapiji z dodajanjem zdravila MYLOTARG (3 leta: 50,6 % v primerjavi s 44,0 %; HR 0,838; 95 % IZ: 0,706; 0,995; p = 0,0431) pri AML de novo zaradi zmanjšanega tveganja ponovitve bolezni s trendom daljšega OS v skupini, ki je prejemala zdravilo MYLOTARG, kar pa ni bilo statistično značilno (3 leta: 72,4 % v primerjavi s 67,6 %; HR 0,904; 95 % IZ: 0,721; 1,133; p = 0,3799).
English: In the combination therapy study, in patients with de novo AML treated with fractionated doses of gemtuzumab ozogamicin in combination with chemotherapy (N=131), 102 (77.9%) patients experienced all causality severe (Grade ≥ 3) infections.
Slovenian: V študiji kombiniranega zdravljenja pri bolnikih z AML de novo, ki so jo zdravili s frakcioniranim odmerjanjem gemtuzumab ozogamicina v kombinaciji s kemoterapijo (n = 131), so se pri 102 bolnikih (77,9 %) pojavile hude okužbe (stopnje ≥ 3) iz vseh vzrokov.
English: Number of events, n (%) Median EFS in months [95% CI]a, 2-year EFS probability[95% CI]b 3-year EFS probability [95% CI]b
Slovenian: število dogodkov, n (%) mediano EFS v mesecih [95 % IZ] verjetnost 2-letnega EFS [95 % IZ] verjetnost 3-letnega EFS [95 % IZ]
English: • Doses administered by syringe must utilize small bore infusion lines (microbore) with an in-line, low protein-binding 0.2 micron polyethersulphone (PES) filter.
Slovenian: • Če za odmerjanje uporabljate brizgo, morate uporabiti infuzijske cevke z majhno odprtino (mikroodprtino) skupaj z zaporedno vključenim 0,2-mikronskim polietersulfonskim (PES) filtrom, ki veže beljakovine z nizko molekulsko maso.
English: The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in monotherapy studies were infection, haemorrhage, multi-organ failure, and VOD.
Slovenian: Najpogostejši (≥ 1 %) neželeni učinki, ki so privedli do trajne prekinitve zdravljenja v študijah monoterapije, so bili okužba, krvavitev, odpoved več organov in VOD.
English: Women of childbearing potential, or partners of females of childbearing potential should be advised to use 2 methods of effective contraception during treatment with MYLOTARG for at least 7 months (females) or 4 months (males) after the last dose.
Slovenian: Ženskam v rodni dobi ali partnerjem žensk v rodni dobi je treba svetovati, naj med zdravljenjem z zdravilom MYLOTARG uporabljajo 2 metodi učinkovite kontracepcije še vsaj 7 mesecev (ženske) ali 4 mesece (moški) po zadnjem odmerku.
English: If you get any side effects, talk to your doctor, pharmacist, or nurse.
Slovenian: Če opazite kateregakoli izmed neželenih učinkov, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
English: The primary metabolic pathway of gemtuzumab ozogamicin is anticipated to be hydrolytic release of N acetyl gamma calicheamicin dimethyl hydrazide.
Slovenian: Pričakovana primarna presnovna pot gemtuzumab ozogamicina je hidrolitska sprostitev N-acetilgama-kaliheamicin dimetilhidrazida.
English: The diluted solution can be refrigerated at 2°C-8°C for up to 12 hours.
Slovenian: Razredčeno raztopino lahko hranite v hladilniku pri temperaturi 2 °C - 8 °C največ 12 ur.
English: If AraC is used for leukoreduction with or without hydroxyurea in patients with previously untreated, de novo hyperleukocytic AML receiving MYLOTARG in combination therapy, apply the following modified schedule (Table 2):
Slovenian: Če pri bolnikih s predhodno nezdravljeno, de novo AML s hiperlevkocitozo, ki prejemajo zdravilo MYLOTARG v kombiniranem zdravljenju, za levkoredukcijo uporabite citarabin s hidroksisečnino ali brez nje, upoštevajte naslednjo prilagojeno shemo (preglednica 2):
English: Due to the risk of VOD/SOS, signs and symptoms of VOD/SOS should be closely monitored; these may include elevations in ALT, AST, total bilirubin, and alkaline phosphatase, which should be monitored prior to each dose of MYLOTARG, hepatomegaly (which may be painful), rapid weight gain, and ascites.
Slovenian: Ti lahko vključujejo povečane vrednosti ALT, AST, celokupnega bilirubina in alkalne fosfataze, ki jih je treba spremljati pred vsakim odmerkom zdravila MYLOTARG, hepatomegalijo (ki je lahko boleča), hitro povečanje telesne mase in ascites.
English: The most frequent (≥ 1%) adverse reactions that led to permanent discontinuation in the combination therapy study were thrombocytopenia, VOD, haemorrhage and infection.
Slovenian: Najpogostejši (≥ 1 %) neželeni učinki, ki so privedli do trajne prekinitve zdravljenja v študijah kombiniranega zdravljenja, so bili trombocitopenija, VOD, krvavitev in okužba.
English: Dextran 40, sucrose, sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous.
Slovenian: Dekstran 40, saharoza, natrijev klorid, natrijev dihidrogenfosfat monohidrat, brezvodni dinatrijev hidrogenfosfat.
English: Appropriate measures to help prevent the development of tumour lysis-related hyperuricaemia, such as hydration, administration of antihyperuricemics (e.g., allopurinol) or other agents for treatment of hyperuricaemia (e.g., rasburicase) must be taken.
Slovenian: Uvesti je treba ustrezne ukrepe za preprečevanje razvoja s tumorsko lizo povezane hiperurikemije, kot sta hidracija in dajanje zdravil proti hiperurikemiji (npr. alopurinola) ali drugih zdravil za zdravljenje hiperurikemije (npr. razburikaze).
English: b. Based on the Cox Proportional Hazards Model Versus daunorubicin+cytarabine.
Slovenian: Na podlagi Coxovega modela sorazmernih tveganj v primerjavi z daunorubicinom + citarabinom.
English: Infusion lines made of PVC (DEHP- or non DEHP-containing), or polyethylene are recommended.
Slovenian: Priporočljivi so infuzijski sistemi, izdelani iz PVC (ki vsebujejo ali ne vsebujejo DEHP) ali polietilena.
English: There have been reports of fatal infusion reactions in the post-marketing setting.
Slovenian: V obdobju trženja zdravila so poročali o reakcijah na infuzijo s smrtnim izidom.
English: What MYLOTARG contains
Slovenian: Kaj vsebuje zdravilo MYLOTARG
English: Nausea Stomatitisp
Slovenian: Okvara ledvic
English: An in-line, low protein-binding 0.2 micron polyethersulphone (PES) filter must be used for infusion of MYLOTARG.
Slovenian: Za infundiranje zdravila MYLOTARG je treba v infuzijskem sistemu uporabiti zaporedno vključeni 0,2-mikronski polietersulfonski (PES) filter, ki veže beljakovine z nizko molekulsko maso.
English: In the consolidation 1 phase of therapy, 94 (96.9%) patients had neutrophil recovery to counts of 500/mm3, and 91 (94%) patients recovered to counts of 1,000/mm3.
Slovenian: V 1. konsolidacijski fazi zdravljenja se je pri 94 bolnikih (96,9 %) število nevtrofilcev povečalo na 500/mm 3, pri 91 bolnikih (94 %) pa na 1.000/mm 3.
English: When gemtuzumab ozogamicin is administered at 3 mg/m2 on Days 1, 4, and 7, the Cmax of hP67.6, which would occur at the end of infusion, is predicted to be 0.38 mg/L following the first dose and increased to 0.63 mg/L after the third dose.
Slovenian: 1., 4. in 7. dan, je predvidena vrednost Cmax za hP67.6 ob koncu infundiranja 0,38 mg/l po prvem odmerku, povečana na 0,63 mg/l po tretjem odmerku.
English: In the combination therapy study (N=131), all grades and Grade 3/4 bleeding/haemorrhagic reactions were reported in 118 (90.1%) and 27 (20.6%) patients, respectively.
Slovenian: V študiji kombiniranega zdravljenja (n = 131) so pri 118 bolnikih (90,1 %) poročali o krvavitvah/hemoragičnih reakcijah vseh stopenj, pri 27 bolnikih (20,6 %) pa o krvavitvah/hemoragičnih reakcijah stopnje 3/4.
English: 3 mg/m2/dose (up to a maximum of one 5 mg vial) on Days 3, 6, and 9
Slovenian: 3 mg/m2/odmerek (do največ ene 5 mg viale) na 3., 6. in 9. dan
English: Based on population pharmacokinetic (PK) analyses, the combination of gemtuzumab ozogamicin with hydroxyurea, DNR, and AraC is not predicted to cause clinically meaningful changes in the PK of hP67.6 or unconjugated calicheamicin.
Slovenian: Na podlagi populacijskih farmakokinetičnih analiz kombinacija gemtuzumab ozogamicina s hidroksisečnino, daunorubicinom in citarabinom predvidoma ne povzroči klinično pomembnih sprememb v farmakokinetiki hP67.6 ali nekonjugiranega kaliheamicina.
English: • If the reconstituted solution cannot be used immediately, it may be stored in the original vial for up to 6 hours in a refrigerator (2°C-8°C) with not more than 3 hours at room temperature (below 25°C).
Slovenian: • Če rekonstituirane raztopine ne morete uporabiti takoj, jo lahko hranite v originalni viali v hladilniku (2 °C - 8 °C) največ 6 ur in največ 3 ure na sobni temperaturi (do 25 °C).
English: • Gently invert the infusion container to mix the diluted solution.
Slovenian: • Infuzijski vsebnik nežno zasukajte, da zmešate razredčeno raztopino.
English: Overall survival
Slovenian: Verjetnost preživetja
English: c. Venoocclusive liver disease includes the following reported PTs: Venoocclusive disease and Venoocclusive liver disease*.
Slovenian: Venookluzivna bolezen jeter vključuje naslednja PT, o katerih so poročali: venookluzivna bolezen in venookluzivna bolezen jeter t.
English: See also section 6.3 for dilution, storage, and infusion information.
Slovenian: Za informacije o redčenju, shranjevanju in infundiranju glejte tudi poglavje 6.3.
English: Effect on drug transporter substrates
Slovenian: Učinek na substrate prenašalcev zdravil
English: No adjustment of the starting dose is required in patients with hepatic impairment defined by total bilirubin ≤ 2 × upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine aminotransferase (ALT)
Slovenian: Pri bolnikih z okvaro jeter, ki je opredeljena kot celokupni bilirubin ≤ 2 × zgornja meja normale (ZMN) in vrednost aspartat-aminotransferaze (AST)/alanin-aminotransferaze (ALT) ≤ 2,5 × ZMN, prilagajanje začetnega odmerka ni potrebno.
English: m. Hypertension includes the following reported PTs: Hypertension and Blood pressure increased.
Slovenian: Hipertenzija vključuje naslednja PT, o katerih so poročali: hipertenzija in zvišanje krvnega tlaka.
English: Appropriate measures to help prevent the development of tumour lysis-related hyperuricaemia, such as hydration, administration of antihyperuricemic or other agents for treatment of hyperuricaemia should be taken (see section 4.4).
Slovenian: Uvesti je treba ustrezne ukrepe za preprečevanje razvoja s tumorsko lizo povezane hiperurikemije, kot sta hidracija in dajanje zdravil proti hiperurikemiji ali drugih zdravil za zdravljenje hiperurikemije (glejte poglavje 4.4).
English: After gemtuzumab ozogamicin binds to the target it is internalised and N-acetyl calicheamicin is released by hydrolytic cleavage.
Slovenian: Po tem, ko se gemtuzumab ozogamicin veže na tarčo, se internalizira, s hidrolitsko cepitvijo pa se sprosti N-acetil-kaliheamicin.
English: Abbreviations: CR=complete remission; CRp=complete remission with incomplete platelet recovery; CI=confidence interval; EFS=event-free survival; mITT=modified intent-to-treat; n=number; N=number; NE= not estimable; OS=overall survival; RFS=relapse-free survival.
Slovenian: Okrajšave: CR = popolna remisija; CRp = popolna remisija z delnim povečanjem števila trombocitov; IZ = interval zaupanja; EFS = preživetje brez dogodkov ; mITT = modificirana populacija, ki so jo nameravali zdraviti; n = število; NE = ni mogoče oceniti; OS = celokupno preživetje; RFS = preživetje brez ponovitve bolezni.
English: v. Erythema includes the following reported PTs: Catheter site erythema, Erythema and Infusion site erythema#.
Slovenian: Eritem vključuje naslednje PT, o katerih so poročali: eritem na mestu vstopa katetra, eritem in eritem na mestu infundiranja w.
English: Male reproductive effects (testes, epididymides, seminal vesicles) in monkeys were observed at approximately 66 times the human clinical exposure after the third dose of 3 mg/m2).
Slovenian: Učinke na razmnoževanje pri samcih opic (testisi, epididimisi, semenjaki) so opazili pri približno 66-kratniku klinične izpostavljenosti pri ljudeh po tretjem odmerku 3 mg/m
English: l. Hypotension includes the following reported PTs: Hypotension and Blood pressure decreased.
Slovenian: Hipotenzija vključuje naslednja PT, o katerih so poročali: hipotenzija in zmanjšanje krvnega tlaka.
English: MYLOTARG is a powder for concentrate for solution for infusion.
Slovenian: Zdravilo MYLOTARG je prašek za koncentrat za raztopino za infundiranje.